Cytyc Army Contract For ThinPrep Pap Test Mobilizes Stock In September
This article was originally published in The Gray Sheet
Executive Summary
Cytyc's exclusive contract to supply the U.S. Army with ThinPrep Pap tests appeared to be the driving force behind the firm's 10.6% stock boost in September. The issue gained $2.58 to close at $26.81 for the month.
You may also be interested in...
St. Jude Paces Large Caps In Q3; Index Composite Bucks Market Decline
Medicare's decision to cover anticoagulation home monitoring for patients with mechanical heart valves, combined with dependable operating results and a promising product portfolio made St. Jude Medical a third-quarter standout among the 27 issues on "The Gray Sheet" Index of NYSE and AMEX device and diagnostics stocks.
Lifecore Intergel Approvable Despite FDA Objections, MDDR Panel Says
Lifecore Biomedical's Gynecare Intergel adhesion prevention solution appears closer to FDA approval following a determination by the agency's Medical Devices Dispute Resolution Panel (MDDRP) that the firm demonstrated a statistically significant treatment effect.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.